• Optimizing G418 Sulfate Selection: Protocols and Troubleshoo

  2026-04-29

  G418 Sulfate (Geneticin) stands out as an ultra-pure selection antibiotic for genetic engineering, enabling precise cell line development and advanced antiviral research. This article delivers actionable protocols, advanced troubleshooting, and evidence-driven insights—bridging iPSC workflows and viral inhibition strategies for translational impact.

• WAY-100635: Unlocking Advanced Behavioral 5-HT1A Assays

  2026-04-28

  Explore the profound impact of WAY-100635, a potent serotonin receptor antagonist, on neuroscience receptor pharmacology and behavioral assay precision. This article delivers in-depth analysis, unique protocol guidance, and a fresh application focus distinct from existing resources.

• PK/PD Targets for Gamithromycin Against S. suis in Piglets

  2026-04-28

  This study establishes pharmacodynamic target exposures and PK/PD cutoffs for gamithromycin against Streptococcus suis in piglets, defining serum AUC/MIC ratios for stasis and bactericidal effects. These findings inform dose optimization and susceptibility breakpoints, with implications for antibiotic resistance research and translational models.

• Biotin-XX Tyramide Reagent: High-Fidelity Cell Surface Label

  2026-04-27

  Biotin-XX Tyramide Reagent enables sensitive, membrane-impermeant cell surface protein labeling using tyramide signal amplification. This reagent is optimized for HRP-catalyzed proximity labeling, offering enhanced specificity in immunohistochemistry and in situ hybridization. Its performance and limitations are supported by recent peer-reviewed evidence.

• SU5416 (Semaxanib): VEGFR2 Inhibitor for Angiogenesis Resear

  2026-04-27

  SU5416 (Semaxanib) is a potent and selective VEGFR2 inhibitor with validated anti-angiogenic and immune-modulatory properties. Demonstrated efficacy includes suppression of VEGF-induced endothelial proliferation and tumor vascularization. Its high selectivity and dual mechanism make it a central tool for cancer and vascular biology research.

• Bromodomain Inhibitor, (+)-JQ1: Optimized Workflows & Troubl

  2026-04-26

  Unlock the full potential of Bromodomain Inhibitor, (+)-JQ1 for targeted cancer research, apoptosis assays, and non-hormonal male contraception. This guide translates cutting-edge BRD4 inhibition insights into actionable workflows and troubleshooting strategies, empowering biomedical labs to achieve reproducible, high-impact results.

• Shufeng Xingbi Therapy Modulates Immunity and Microbiota in

  2026-04-25

  This study investigates the effects of Shufeng Xingbi Therapy on Th1/Th2 immune balance and gut microbiota composition in an ovalbumin-induced rat model of allergic rhinitis. By integrating immunological and microbiome analyses, the research provides novel insights into how traditional therapies may alleviate allergy-driven inflammation through immune modulation and microbiota restructuring.

• Canagliflozin Reshapes Mitochondria in Diabetic Kidney Disea

  2026-04-24

  This study demonstrates that Canagliflozin, a potent SGLT2 inhibitor, not only reduces albuminuria but also remodels mitochondrial structure and function in proximal tubular cells of hypertensive–diabetic mice. Findings suggest that these mitochondrial changes are mechanistically linked to renal protection, informing future diabetes research beyond glycemic endpoints.

• Fluorescein Tyramide: Amplifying Insights in Neurobehavioral

  2026-04-24

  This article explores the strategic use of Fluorescein Tyramide as a fluorescent labeling dye to drive signal amplification in immunohistochemistry, in situ hybridization, and flow cytometry. Drawing on recent advances in oxytocin signaling and early life adversity research, we examine how cutting-edge signal amplification methods unlock previously inaccessible cellular insights, inform translational neuroscience, and chart a path forward for innovative study design.

• Tigecycline: Mechanistic Insights and Strategies for MDR Mod

  2026-04-23

  Explore the unique mechanistic profile of Tigecycline, a glycylcycline antibiotic, and discover advanced strategies for multidrug-resistant (MDR) infection models. This article provides evidence-based guidance and new perspectives for optimizing complex antimicrobial research.

• MLN2238: Proteasome β5 Subunit Inhibitor for Oncology Workfl

  2026-04-23

  MLN2238 stands out as a next-generation, reversible proteasome β5 subunit inhibitor with robust efficacy in multiple myeloma and lymphoma models, including bortezomib-resistant contexts. This article delivers a practical, evidence-driven guide on leveraging MLN2238 in advanced oncology and proteotoxic stress research, complete with workflow enhancements, troubleshooting, and translational insights.

• Antimycin A4 as an ATP-Citrate Lyase Inhibitor: Applied Work

  2026-04-22

  Antimycin A4 offers unique dual inhibition of ATP-citrate lyase and the mitochondrial respiratory chain, enabling precise dissection of energy metabolism and lipid biosynthesis in cellular models. This article translates cutting-edge mechanistic research into actionable protocols, troubleshooting tips, and advanced applications for metabolic and mitochondrial studies.

• Optimizing hESC Differentiation to Trophoblasts: Protocol Co

  2026-04-22

  This study systematically compares four protocols for directing human embryonic stem cells (hESCs) toward trophoblast lineages in vitro using BMP4 and dual inhibition of activin/nodal and FGF2 signaling. The nuanced analysis reveals that while all methods promote trophoblast marker expression, each protocol yields distinct differentiation efficiencies and cellular subtypes—offering critical guidance for experimental design in placental and developmental biology.

• Alisol A Modulates Cholesterol and Autophagy in Vascular Cog

  2026-04-21

  This study elucidates the neuroprotective mechanisms of Alisol A in atherosclerosis-related vascular cognitive impairment (VCI). By activating the AMPK/NAMPT/SIRT1 pathway, Alisol A restores cholesterol homeostasis and mitophagy, attenuating cognitive decline in a high-fat diet/Ldlr-/- mouse model. These findings highlight new therapeutic avenues and cross-talk between metabolic and neurodegenerative disease mechanisms.

• Gefitinib (ZD1839) in Tumor Microenvironment-Driven Resistan

  2026-04-21

  Explore how Gefitinib (ZD1839) enables precise EGFR pathway inhibition and uncovers resistance mechanisms in tumor microenvironments. This in-depth article offers actionable, evidence-driven strategies for leveraging APExBIO's Gefitinib in advanced assembloid models—beyond standard EGFR inhibition.

406 records 17/28 page Previous Next First page 上5页 1617181920 下5页 Last page